Analysts Set Expectations for Oculis Holding AG's FY2025 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS - Free Report) - Equities researchers at HC Wainwright issued their FY2025 earnings per share estimates for shares of Oculis in a research report issued on Monday, May 13th. HC Wainwright analyst Y. Chen forecasts that the company will earn ($1.62) per share for the year. HC Wainwright currently has a "Buy" rating and a $28.00 target price on the stock. The consensus estimate for Oculis' current full-year earnings is ($1.72) per share.

Several other brokerages also recently issued reports on OCS. Chardan Capital reissued a "buy" rating and set a $30.00 price objective on shares of Oculis in a research note on Tuesday, March 19th. Robert W. Baird cut their price target on shares of Oculis from $64.00 to $35.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 19th. Finally, Wedbush reaffirmed an "outperform" rating and set a $29.00 price target on shares of Oculis in a research note on Wednesday, March 6th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $30.17.

Oculis Price Performance

Shares of NASDAQ OCS traded up $0.09 on Tuesday, hitting $12.16. The company's stock had a trading volume of 41,779 shares, compared to its average volume of 45,737. Oculis has a 12-month low of $9.05 and a 12-month high of $14.50. The company has a market capitalization of $492.48 million, a price-to-earnings ratio of -6.78 and a beta of 0.53. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.71 and a quick ratio of 4.71. The stock has a 50 day moving average of $11.90 and a 200-day moving average of $11.43.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings results on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.04. Oculis had a negative net margin of 6,712.02% and a negative return on equity of 52.72%. The business had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.28 million.

Institutional Trading of Oculis

Institutional investors have recently added to or reduced their stakes in the business. Wolverine Asset Management LLC bought a new position in shares of Oculis in the third quarter valued at approximately $77,000. Compagnie Lombard Odier SCmA increased its position in Oculis by 47.3% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company's stock worth $1,053,000 after acquiring an additional 30,750 shares during the period. abrdn plc bought a new position in Oculis during the fourth quarter worth $15,980,000. Finally, Searle & CO. bought a new position in Oculis during the fourth quarter worth $112,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.